GlassScriptPhysician profile
Maritere Rochet
NPI 1487738688
$1,340.92
in general payments reported to CMS, 2019-2025
28 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $188 · 2021: $12.37 · 2022: $32.51 · 2023: $305 · 2024: $212 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.25 | 2023-2024 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $204.46 | 2019-2023 | Otezla, Enbrel |
| Madrigal Pharmaceuticals | $127.12 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $82.58 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $76.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.44 | 2019 | |
| Exact Sciences Corporation | $46.51 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.87 | 2019-2020 | |
| Amarin Pharma, INC. | $37.41 | 2020 | |
| Lilly USA, LLC | $32.05 | 2023 | Taltz, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $29.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.14 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $29.09 | 2023 | Opsumit |
| Novartis Pharmaceuticals Corporation | $29.01 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.92 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $26.79 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.21 | 2023 | |
| Sobi, INC | $18.47 | 2022 | |
| Pfizer INC. | $16.41 | 2019 | |
| Astellas Pharma US INC | $15.47 | 2023 | Veozah |
| Mannkind Corporation | $15.16 | 2020 | |
| Metuchen Pharmaceuticals | $14.14 | 2019 | |
| Lucid Diagnostics INC. | $13.73 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.29 | 2019 | |
| Vivus LLC | $11.96 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritere Rochet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.